Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

Structure Therapeutics (GPCR, NASDAQ) has fallen sharply over the past three months — down 31.1%, including a 27.0% decline in the last month — with the stock at $35.93, an RSI of 18, and trading 34.0% below its 200-day SMA. The clinical-stage biotech, which is developing oral therapeutics for chronic diseases including obesity, generated no revenue in the trailing twelve months and posted a Q2 net loss of $106.2M, wider than the prior quarter's $76.2M, while missing EPS estimates in each of its last four reports. Liquidity remains substantial, with $272.6M in cash, minimal debt of $6.2M, and a current ratio of 20.75, against a quarterly free cash outflow of $120.2M. The company's market cap stands at $2.56B, with an analyst target of $105.78, and recent news flow has centered on a CMO's planned sale of 4,008 shares (~$140K) under a Rule 10b5-1 plan.